New triple therapy trial offers hope for Tough-to-Treat neuroendocrine cancers
NCT ID NCT07156019
Summary
This study is testing whether combining three different cancer drugs—sintilimab, surufatinib, and temozolomide—can help control advanced neuroendocrine carcinoma that has worsened after initial treatment. It will enroll 32 adults whose cancer cannot be surgically removed or has spread, to see if this combination can shrink tumors and extend life. The trial will closely monitor how well the treatment works and what side effects patients experience.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE CARCINOMAS (NEC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.